Literature DB >> 6322422

Investigation of vaccinia virus DNA replication employing a conditional lethal mutant defective in DNA.

B G Pogo, E M Berkowitz, S Dales.   

Abstract

After infection of L cells with the DNA-defective temperature-sensitive (ts) mutant 6389 of vaccinia virus, [3H]thymidine incorporation into cytoplasmic DNA is inhibited at 39 degrees, but resumes upon shiftdown to 32 degrees, the permissive temperature. Following a 30-min lag period DNA synthesis is linear and contingent upon continuous protein synthesis. Sedimentation analysis of nascent DNA labeled during 10 to 60-min pulses revealed that the mutant molecules are produced at a slower rate, but are approximately the same size as those of wild-type vaccinia, synthesized under the same circumstances. During more prolonged incubation beyond 60 min, labeled DNA molecules sedimenting more rapidly than mature, full-length virus genomes are observed. The integration of mutant DNA into mature virions is less rapid than that of the wide-type DNA. Upon extraction from the virosomes, the ts6389 DNA sediments as both genome-size and larger, faster sedimenting DNA. Upon treatment with restriction endonucleases, the ts6389 virosomal DNA exhibited an additional fragment after separation on agarose gels, perhaps as a consequence of fusion between the terminal fragments of the molecule. Taken together these observations suggest that concatemeric intermediates are formed during vaccinia DNA replication. By measuring the radioactivity incorporated into the fragments and subfragments of the molecules labeled during the first round of replication, the initiation site of replication can be localized to a region within the terminal 150 bp.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6322422     DOI: 10.1016/0042-6822(84)90048-5

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  14 in total

1.  Genetic analysis of the vaccinia virus I6 telomere-binding protein uncovers a key role in genome encapsidation.

Authors:  Olivera Grubisha; Paula Traktman
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 2.  Poxvirus DNA replication.

Authors:  Bernard Moss
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-09-01       Impact factor: 10.005

3.  Vaccinia virus DNA replication: two hundred base pairs of telomeric sequence confer optimal replication efficiency on minichromosome templates.

Authors:  S Du; P Traktman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

4.  Mutations in active-site residues of the uracil-DNA glycosylase encoded by vaccinia virus are incompatible with virus viability.

Authors:  K S Ellison; W Peng; G McFadden
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

5.  Delineation of the viral products of recombination in vaccinia virus-infected cells.

Authors:  D D Spyropoulos; B E Roberts; D L Panicali; L K Cohen
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

6.  Sequence-nonspecific replication of transfected plasmid DNA in poxvirus-infected cells.

Authors:  A M DeLange; G McFadden
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

7.  Identification of temperature-sensitive mutants of vaccinia virus that are defective in conversion of concatemeric replicative intermediates to the mature linear DNA genome.

Authors:  A M DeLange
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

8.  Vaccinia virus telomeres: interaction with the viral I1, I6, and K4 proteins.

Authors:  J DeMasi; S Du; D Lennon; P Traktman
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  Mapping vaccinia virus DNA replication origins at nucleotide level by deep sequencing.

Authors:  Tatiana G Senkevich; Daniel Bruno; Craig Martens; Stephen F Porcella; Yuri I Wolf; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-18       Impact factor: 11.205

10.  Poxvirus DNA primase.

Authors:  Frank S De Silva; Whitney Lewis; Peter Berglund; Eugene V Koonin; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.